Solara Active Pharma Sciences Receives Rs 4.88 Crore in First Call Money, Converts 3.71 Lakh Partly Paid-Up Shares Aug 16, 2025
Solara Active Pharma Sciences has received Rs 4.88 crore as first call money for 3,71,779 partly paid-up Rights Equity Shares, converting them from Rs 3.50 to Rs 7 paid-up status. This action has increased the company's paid-up capital to Rs 44.47 crore. The company's capital structure now includes 3,61,54,267 fully paid-up equity shares, 1,17,61,546 partly paid-up Rights Equity Shares (Rs 7 paid-up), and 2,37,209 partly paid-up Rights Equity Shares (Rs 3.5 paid-up). Solara will proceed with necessary steps for corporate actions and obtain listing and trading approvals for the converted shares.
Solara Active Pharma Sciences Reports Strong Q1 with 15% Revenue Growth and Highest PAT in 12 Quarters Jul 29, 2025
Solara Active Pharma Reports Strong Q1 Results with 15% Revenue Growth and Positive Earnings Jul 25, 2025
Solara Active Pharma Sciences Shifts Focus to High-Value Markets, Plans Demerger Jul 06, 2025
Solara Active Pharma Sciences Downgrades FY25 Financial Outlook May 15, 2025
Solara Active Pharma Sciences Ltd. (SAPS) reported Q4 FY2024 results with a net loss of ₹200 crore, improved from ₹255 crore loss year-over-year. Revenue declined 9.70% to ₹270 crore. Q4 EBITDA was ₹59.20 crore with an improved Operating Profit Margin of 19.21%. Annual performance for FY24 showed challenges with revenue down 11.74% to ₹1,294.30 crore and a significant net loss of ₹567 crore.
12May 25
Solara Active Pharma's Ambernath Facility Passes USFDA Inspection with Flying Colors
Solara Active Pharma Sciences' Ambernath facility has successfully passed a United States Food and Drug Administration (USFDA) inspection without any Form 483 observations. This outcome indicates full compliance with USFDA's regulatory standards, potentially boosting the company's regulatory confidence, market reputation, and business opportunities in the U.S. pharmaceutical market. The clean inspection ensures operational continuity and reflects the high quality of Solara's manufacturing processes and compliance systems.
10May 25
Solara Active Pharma's Ambernath Facility Passes USFDA Inspection with Flying Colors
Solara Active Pharma Sciences Limited's Ambernath facility successfully completed a United States Food and Drug Administration (USFDA) inspection with no Form 483 observations. This outcome demonstrates the facility's compliance with stringent regulatory standards and could boost market confidence, potentially leading to expanded business opportunities in regulated markets, particularly the United States. The clean inspection report highlights Solara's commitment to maintaining high-quality manufacturing standards in the pharmaceutical industry.
24Feb 25
Solara Active Pharma Sciences to Shut Down Brazilian Subsidiary
Solara Active Pharma Sciences' board has approved the closure of its subsidiary in Brazil, Solara Active Pharma Sciences Ltda. This decision marks a significant shift in the company's international strategy, potentially impacting its operations in the South American market. The closure could lead to reduced operational costs, a shift in focus to other markets, and possible restructuring of the global supply chain. The move signals a strategic realignment for Solara, with potential implications for its financial performance and market position.
21Feb 25
Solara Active Pharma Sciences Announces Major Restructuring and Leadership Changes
Solara Active Pharma Sciences Limited has announced significant corporate changes following a board meeting on February 21, 2025. The company will close its non-operational Brazilian subsidiary. Key leadership appointments include Sandeep Rao as new MD & CEO, Sarat Kumar as CFO, and Vishal Mathur as CBO. The board approved granting 3,50,000 stock options to employees at Rs. 375 per option. Various committees have been reconstituted to reflect these changes.